Shockwave Medical, Inc. (NASDAQ:SWAV) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET

Company Participants

Debbie Kaster - Vice President, Investor Relations

Doug Godshall - President and Chief Executive Officer

Isaac Zacharias - President and Chief Commercial Officer

Dan Puckett - Chief Financial Officer

Robert Fletcher - Senior Vice President, Marketing and Market Access

Conference Call Participants

William Plavonic - Canaccord Genuity

Travis Steed - Bank of America

Adam Maeder - Piper Sandler

Michael Polark - Wolfe Research

Lawrence Biegelsen - Wells Fargo

Imron Zafar - Deutsche Bank

Mike Matson - Needham & Company

Operator

Good afternoon and welcome to Shockwave's Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes.

I would now like to turn the call over to your host, Debbie Kaster, Vice President of Investor Relations at Shockwave for a few introductory comments.

Debbie Kaster

Thank you all for participating in today's call. Joining me today from Shockwave Medical are Doug Godshall, President and Chief Executive Officer; Isaac Zacharias, President and Chief Commercial Officer; and Dan Puckett, Chief Financial Officer.

Earlier today, Shockwave released financial results for the quarter ended June 30th, 2023. A copy of the press release is available on Shockwave's website.

Before we begin, I would like to remind you that management will make statements during this call that includes forward-looking statements within the meaning of Federal Securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.

Any statements contained in this call other than statements of historical fact are forward-looking statements. All forward-looking statements, including without limitation, statements relating to our sales and operating trends, business and hiring prospects, financial and revenue expectations, reimbursement proposals, future product development and approvals and the integration of Neovasc and its technologies into our business are based upon our current estimates and various assumptions.

These statements involve material risks and uncertainties, including the impact of macroeconomic conditions and global events such as the COVID-19 pandemic that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements.

Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the Risk Factors section of our annual report on Form 10-K on file with the SEC and available on EDGAR and in our other reports filed periodically with the SEC.